Lora Stewart, MD
Allergy & Immunology · Lone Tree, CONPI 1346201985
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,484 of the $6,344 with a category attached, or 70.7%. 30 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 28.8% of the total. Reporting peaked in 2021 at $2,324 and has fallen 78.1% since, to $509 in 2025.
Across 245 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$826
- AstraZeneca$741
- GSK$595
- Pharming Healthcare, Inc.$338
- Sanofi$288
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$1,68026%
- Food & beverage$4,48471%
- Education$1803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 10 | $1,826 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $826 |
| AstraZeneca | 34 | $741 |
| GSK | 45 | $595 |
| Pharming Healthcare, Inc. | 10 | $338 |
| Sanofi | 14 | $288 |
| Novartis | 12 | $248 |
| CSL Behring | 9 | $239 |
| Optinose US, Inc. | 11 | $192 |
| Sanofi-aventis U.S. LLC | 2 | $164 |
| Genentech USA, Inc. | 7 | $119 |
| Pfizer | 6 | $96 |
| Regeneron Healthcare Solutions, Inc. | 4 | $95 |
| Kaleo, Inc. | 4 | $85 |
| Boehringer Ingelheim | 4 | $72 |
| Grifols USA, LLC | 3 | $72 |
| Amgen | 3 | $59 |
| Shire North American Group Inc | 2 | $31 |
| Ionis Pharmaceuticals, Inc. | 1 | $31 |
| Cycle Pharmaceuticals Inc | 1 | $29 |
| Greer Laboratories, Inc. | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Blueprint Medicines Corporation | 1 | $25 |
| AbbVie | 1 | $23 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
| QOL Medical, LLC | 1 | $20 |
| Bio Products Laboratory USA, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
| Organon | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ArmonAir Digihaler$1,680
- AirDuo RespiClick$1,680
- ProAir Digihaler$1,680
- JOENJA$122
How this compares
$6,344 in reported general payments places this provider in the 65th percentile of 89 allergy & immunology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 14 | $385,025 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $80,261 |
| XolairOmalizumab | 14 | $38,177 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $31,199 |
| Spiriva RespimatTiotropium Bromide | 26 | $22,331 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,675 |
| Arnuity ElliptaFluticasone Furoate | 34 | $8,861 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $7,760 |
| Qvar RedihalerBeclomethasone Dipropionate | 22 | $7,200 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,164 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $4,626 |
| DuleraMometasone/Formoterol | 12 | $3,856 |
| Epinephrine | 16 | $2,918 |
| Pulmicort FlexhalerBudesonide | 11 | $2,846 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Cuvitru | $826 | $416,22426 claims |
| CSL BehringHizentra | $239 | $80,26126 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $595 | $26,69961 claims |
| Boehringer IngelheimSpiriva Respimat | $72 | $22,33126 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $741 | $10,60638 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $1,826 | $7,20022 claims |
| MerckDulera | $17 | $3,85612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 89 allergy & immunology providers in Colorado.
Other allergy & immunology in Lone Tree
- Rohit KatialDenver$758K
- Nicole BarberisLakewood$351K
- Christopher WebberColorado Springs$350K
- Jeffrey RumbyrtLakewood$348K
- Eric CaplanColorado Springs$290K
- Eileen WangDenver$274K
- Donald LeungDenver$208K
- Robert NathanColorado Springs$130K
- Katherine McCormackLouisville$90K
- Flavia HoyteDenver$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.